Evidence map›Paper›PMID 42702820›Full record

ArticleOncoimmunology2026

Broad targeting of HPV E proteins by intratumoral and systemic B cell responses in HPV+ head and neck cancer.

Ilham Bahhar, Jacob P Conarty, Songzhu Zhao, Mengda Yu, Bhavna Kumar, James W Rocco, Andreas Wieland

Abstract read
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ilham BahharDepartment of Otolaryngology-Head and Neck Surgery, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Jacob P ConartyDepartment of Otolaryngology-Head and Neck Surgery, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Songzhu ZhaoDepartment of Biomedical Informatics and Center for Biostatistics, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Mengda YuDepartment of Biomedical Informatics and Center for Biostatistics, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Bhavna KumarDepartment of Otolaryngology-Head and Neck Surgery, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
James W RoccoDepartment of Otolaryngology-Head and Neck Surgery, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Andreas WielandDepartment of Otolaryngology-Head and Neck Surgery, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUM1TR004548 · NCATS · OHIO STATE UNIVERSITY · PI CYNTHIA A GERHARDT, JULIE A. JOHNSON · 2023 to 2026
$22.0M
CTSA Predoctoral T32 at the Ohio State UniversityT32TR004543 · NCATS · OHIO STATE UNIVERSITY · PI GINNY L BUMGARDNER · 2023 to 2026
$1.2M
Targeting of HPV oncoproteins using novel antibody therapeuticsR03DE034425 · NIDCR · OHIO STATE UNIVERSITY · PI WIELAND, ANDREAS MICHAEL · 2025 to 2025
$315k
NCATS NIH HHS T32 TR004543NCATS NIH HHS UM1 TR004548NCI NIH HHS P30 CA016058NIDCR NIH HHS R03 DE034425
6 · The paper itself

Abstract

B cells can account for a substantial proportion of tumor-infiltrating lymphocytes (TILs) and have been associated with improved outcomes in several malignancies. Yet, their antigen specificity, a key factor for ascribing a distinct function, is mostly unknown. Here, we demonstrate that in tumors of patients with human papillomavirus-positive head and neck cancer (HPV+ HNC) a substantial proportion of intratumoral antibody-secreting cells (ASCs) are specific for HPV E proteins. Using IgG ELISpots on TILs, we show that HPV E protein-specific ASCs are detectable in virtually all patients and can account for up to almost a third of all intratumoral IgG+ ASCs. ASC responses against the viral proteins E1 and E2 consistently outnumbered those against the classic oncoproteins E6 and E7. HPV-specific intratumoral ASCs correlated strongly between primary tumor and metastatic lymph nodes as well as with plasma IgG titers, indicating that intratumoral tumor-specific ASCs, at least partially, contribute to systemic anti-tumor responses. To further resolve the makeup of tumor-specific antibody responses, we developed a novel Multiplex Antigen Flow-based ImmunoAssay (MAFIA) enabling simultaneous and standardized quantification of HPV E-specific antibodies across all major Ig isotypes and IgG subclasses. Applying MAFIA to plasma samples of patients with HPV+ HNC revealed that HPV-specific plasma antibodies mainly consisted of IgG1, IgG3, and IgA, with the highest median responses directed against E1 and E2. Overall, our study delineates the antigenic hierarchy and makeup of HPV-specific humoral responses in HPV+ HNC, both intratumorally and systemically, thus providing a framework for future biomarker as well as next-generation therapeutics development.

Indexed as

B-LymphocytesHead and Neck NeoplasmsHuman Papillomavirus VirusesLymphocytes, Tumor-InfiltratingOncogene Proteins, ViralPapillomavirus InfectionsAntibody-Producing CellsFemaleHumansImmunoglobulin GMaleImmunoglobulin GOncogene Proteins, ViralB-cell responseshead and neck cancerHuman papillomavirusserologyTME

Identifiers

PMID42702820
PMCPMC13556934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.